Close Menu

NEW YORK – Transgene on Tuesday reported that the combination of its therapeutic vaccine TG4001 and the monoclonal antibody avelumab (EMD Serono/Pfizer's Bavencio) demonstrated activity in patients with previously treated, recurrent or metastatic human papillomavirus-related cancers.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.